Abdominal pain in quiescent inflammatory bowel disease
OBJECTIVES: Inflammation is an important driver of abdominal pain in inflammatory bowel disease (IBD). However, some patients in remission still experience pain. We aimed to identify risk factors associated with abdominal pain in quiescent IBD (QP-IBD) and to characterize differences from patients with active disease experiencing pain (AP-IBD).
METHODS: We performed a retrospective analysis utilizing data from our institution's IBD Natural History Registry (January 1, 2015-August 31, 2018). Endoscopic evaluation, concurrent laboratory studies, and validated surveys were completed by participants. Demographic and clinical data were also abstracted.
RESULTS: We recruited 122 patients with quiescent disease (65f:57 m; 93CD:26UC:3Indeterminate) for participation in this study, 74 (60.7%) had QP-IBD. QP-IBD patients were more likely to have anxiety/depression (71.6% vs. 25.0%, p < 0.001) or to use antidepressants (47.3% vs. 22.9%, p < 0.010), opiates (18.9% vs. 2.1%, p < 0.010), other pain medications (50.0% vs. 18.8%, p < 0.010), or corticosteroids (18.9% vs. 2.1%, p < 0.010). On logistic regression analysis, corticosteroid use, anxious/depressed state, and female gender were each independently associated with QP-IBD (p < 0.050 or less). Compared with AP-IBD patients (n = 110, 59f:51 m; 69CD:38UC:3Indeterminate), QP-IBD patients were more likely to use antidepressants (45.6% vs. 26.4%, p < 0.010). Platelet, white blood cell, C-reactive protein, and sedimentation rate levels were all less likely to be elevated in QP-IBD (all p < 0.050), though 44% exhibited pathological elevation in at least one.
DISCUSSION: QP-IBD was independently associated with corticosteroid use, anxiety/depression, and female gender. Compared with AP-IBD, QP-IBD patients were more likely to use antidepressants and less likely to exhibit elevated inflammatory markers. However, many QP-IBD patients still demonstrated pathological elevation of these tests, demonstrating the need to develop new noninvasive screening methods for this condition.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
International journal of colorectal disease - 36(2021), 1 vom: 08. Jan., Seite 93-102 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Coates, Matthew D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Abdominal pain |
|---|
| Anmerkungen: |
Date Completed 23.06.2021 Date Revised 02.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00384-020-03727-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314529225 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314529225 | ||
| 003 | DE-627 | ||
| 005 | 20231225152927.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00384-020-03727-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1048.xml |
| 035 | |a (DE-627)NLM314529225 | ||
| 035 | |a (NLM)32879990 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Coates, Matthew D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Abdominal pain in quiescent inflammatory bowel disease |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.06.2021 | ||
| 500 | |a Date Revised 02.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: Inflammation is an important driver of abdominal pain in inflammatory bowel disease (IBD). However, some patients in remission still experience pain. We aimed to identify risk factors associated with abdominal pain in quiescent IBD (QP-IBD) and to characterize differences from patients with active disease experiencing pain (AP-IBD) | ||
| 520 | |a METHODS: We performed a retrospective analysis utilizing data from our institution's IBD Natural History Registry (January 1, 2015-August 31, 2018). Endoscopic evaluation, concurrent laboratory studies, and validated surveys were completed by participants. Demographic and clinical data were also abstracted | ||
| 520 | |a RESULTS: We recruited 122 patients with quiescent disease (65f:57 m; 93CD:26UC:3Indeterminate) for participation in this study, 74 (60.7%) had QP-IBD. QP-IBD patients were more likely to have anxiety/depression (71.6% vs. 25.0%, p < 0.001) or to use antidepressants (47.3% vs. 22.9%, p < 0.010), opiates (18.9% vs. 2.1%, p < 0.010), other pain medications (50.0% vs. 18.8%, p < 0.010), or corticosteroids (18.9% vs. 2.1%, p < 0.010). On logistic regression analysis, corticosteroid use, anxious/depressed state, and female gender were each independently associated with QP-IBD (p < 0.050 or less). Compared with AP-IBD patients (n = 110, 59f:51 m; 69CD:38UC:3Indeterminate), QP-IBD patients were more likely to use antidepressants (45.6% vs. 26.4%, p < 0.010). Platelet, white blood cell, C-reactive protein, and sedimentation rate levels were all less likely to be elevated in QP-IBD (all p < 0.050), though 44% exhibited pathological elevation in at least one | ||
| 520 | |a DISCUSSION: QP-IBD was independently associated with corticosteroid use, anxiety/depression, and female gender. Compared with AP-IBD, QP-IBD patients were more likely to use antidepressants and less likely to exhibit elevated inflammatory markers. However, many QP-IBD patients still demonstrated pathological elevation of these tests, demonstrating the need to develop new noninvasive screening methods for this condition | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Abdominal pain | |
| 650 | 4 | |a Crohn’s disease | |
| 650 | 4 | |a Inflammatory bowel disease | |
| 650 | 4 | |a Quiescent | |
| 650 | 4 | |a Ulcerative colitis | |
| 700 | 1 | |a Johri, Ansh |e verfasserin |4 aut | |
| 700 | 1 | |a Gorrepati, Venkata Subhash |e verfasserin |4 aut | |
| 700 | 1 | |a Maheshwari, Parth |e verfasserin |4 aut | |
| 700 | 1 | |a Dalessio, Shannon |e verfasserin |4 aut | |
| 700 | 1 | |a Walter, Vonn |e verfasserin |4 aut | |
| 700 | 1 | |a Stuart, August |e verfasserin |4 aut | |
| 700 | 1 | |a Koltun, Walter |e verfasserin |4 aut | |
| 700 | 1 | |a Bernasko, Nana |e verfasserin |4 aut | |
| 700 | 1 | |a Tinsley, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Emmanuelle D |e verfasserin |4 aut | |
| 700 | 1 | |a Clarke, Kofi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of colorectal disease |d 1996 |g 36(2021), 1 vom: 08. Jan., Seite 93-102 |w (DE-627)NLM012646059 |x 1432-1262 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2021 |g number:1 |g day:08 |g month:01 |g pages:93-102 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00384-020-03727-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2021 |e 1 |b 08 |c 01 |h 93-102 | ||